Ponesimod

Ponesimod (pronounced poh-NEH-si-mod) is a selective S1P1 receptor modulator used in the treatment of Multiple Sclerosis. It is an orally active drug developed by Actelion Pharmaceuticals.

Etymology

The term "Ponesimod" is a coined name with no specific etymology. It follows the common naming convention for drugs, typically ending in "-mod" for modulators.

Pharmacology

Ponesimod works by selectively modulating the S1P1 receptor, which is involved in the regulation of certain immune processes. By binding to this receptor, Ponesimod prevents the egress of lymphocytes from lymph nodes, reducing the number of lymphocytes in peripheral blood.

Medical Uses

Ponesimod is used in the treatment of Multiple Sclerosis, a chronic disease that affects the central nervous system. It is specifically indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Side Effects

Common side effects of Ponesimod include respiratory tract infection, liver transaminase elevation, hypertension, and bradycardia at treatment initiation.

Related Terms

• S1P1 receptor
• Multiple Sclerosis
• Actelion Pharmaceuticals
• Lymphocytes
• Central Nervous System

External links

• Medical encyclopedia article on Ponesimod
• Wikipedia's article - Ponesimod

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski